PainReform Overview

  • Founded
  • 2007
Founded
  • Status
  • Public
  • Employees
  • 2
Employees
  • Stock Symbol
  • PRFX
Stock Symbol
  • Share Price
  • $2.89
  • (As of Wednesday Closing)

PainReform General Information

Description

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 4 Bruria Street
  • Tel Aviv 6745442
  • Israel
+972 00-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

PainReform Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.89 $2.81 $2.18 - $7.85 $29.1M 10.1M 222K -$1.21

PainReform Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 28,799 51,681
Revenue 0 0 0 0
EBITDA (3,953) (2,846) (737) (504)
Net Income (4,798) (4,053) (1,279) (828)
Total Assets 21,354 17,801 1,164 81
Total Debt 0 0 6,173 4,520
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PainReform Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PainReform‘s full profile, request access.

Request a free trial

PainReform Executive Team (8)

Name Title Board Seat Contact Info
Eli Hazum Ph.D Chief Technology Officer & Board Member
David Weinstein Ph.D Chief Medical Officer & President
Ehud Geller Ph.D Chief Financial Officer, Finance & Chairman
Sigal Aviel Ph.D Chief Operating Officer, Operations
Ilan Hadar Chief Executive Officer
You’re viewing 5 of 8 executive team members. Get the full list »

PainReform Board Members (7)

Name Representing Role Since
Assif Stoffman Self Board Member 000 0000
Augustine Lawlor Self Board Member 000 0000
Efi Cohen-Arazi Self Board Member 000 0000
Ehud Geller Ph.D PainReform Chief Financial Officer, Finance & Chairman 000 0000
Ellen Baron Ph.D Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

PainReform Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PainReform Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PainReform‘s full profile, request access.

Request a free trial